As the medical community shifts its focus toward precision oncology, a growing consensus has emerged regarding the management of hormone receptor-positive (HR+), HER2-negative breast cancer: many patients are being subjected to the debilitating side effects of chemotherapy when their prognosis might not necessitate such aggressive intervention.
Recent clinical data, including findings from the landmark OPTIMA trial, suggest that a significant majority of high-risk patients may safely bypass traditional chemotherapy, shifting the burden of care toward more refined, targeted endocrine therapies. At the heart of this evolving paradigm is Atossa Therapeutics, a company betting that endoxifen—the active metabolite of the long-standing standard-of-care drug tamoxifen—could become a cornerstone of future breast cancer treatment strategies.
The Evolution of Endocrine Therapy
Since its FDA approval in 1977, tamoxifen has remained a bedrock of breast cancer treatment. By functioning as a Selective Estrogen Receptor Modulator (SERM), it has consistently demonstrated the ability to reduce the risk of cancer recurrence by approximately 32% in the years following initial treatment. For decades, it stood as the gold standard of targeted adjuvant therapy, proving that a five-year course of hormone-modulating drugs could substantially improve long-term survival rates.
However, tamoxifen is a "prodrug," meaning it is not biologically active in its administered form. It relies on the patient’s liver—specifically the CYP2D6 enzyme system—to undergo a complex metabolic process involving roughly 22 different pathways to reach its active state. This reliance on hepatic metabolism is a significant clinical hurdle.
"In order for tamoxifen to work, it requires heavy-duty work by the liver," explains Janet Rea, senior vice president of R&D at Atossa Therapeutics. "If you are not what’s called a ‘good metabolizer’—and there are distinct clinical classifications ranging from ultra-metabolizers to poor metabolizers—you are not going to get the full benefit of tamoxifen because your liver simply cannot process it appropriately."
Endoxifen: Bypassing the Metabolic Bottleneck
Atossa Therapeutics is developing endoxifen as a standalone therapy to eliminate this variability. By delivering the drug in its already active, predominant metabolite form, the company aims to bypass the liver’s metabolic requirements entirely.
The pharmacological concept is not new; researchers have understood since the early 2000s that endoxifen, rather than tamoxifen itself, performs the primary anti-tumor work. The challenge, historically, was pharmaceutical: the active form of endoxifen is highly unstable and degrades when exposed to human stomach acid. Atossa has addressed this by utilizing an innovative enteric coating, which protects the drug through the gastric environment and ensures it is delivered into the gastrointestinal tract where it can be absorbed in its potent, active state.
Chronology of a Shifting Paradigm
The journey toward a refined treatment model for breast cancer has been marked by several key milestones:
- 1977: FDA approves tamoxifen, establishing the foundation for adjuvant endocrine therapy in breast cancer.
- Early 2000s: Scientific consensus solidifies that endoxifen is the primary active agent behind tamoxifen’s efficacy, highlighting the variability in patient metabolic responses due to CYP2D6 enzyme activity.
- 2023: The FDA grants approval to elacestrant, signaling a new era for oral Selective Estrogen Receptor Degraders (SERDs) in advanced or metastatic breast cancer.
- May 2025: Atossa Therapeutics reports favorable Phase 2 results from the I-SPY 2 sub-study, demonstrating that low-dose oral endoxifen effectively reduces markers of tumor cell proliferation.
- 2026 (ASCO Annual Meeting): Presentation of Phase 3 data from the OPTIMA trial reveals that 68% of high-risk patients may safely forgo chemotherapy without compromising five-year invasive disease-free survival rates.
- 2026: Continued clinical advancements for next-generation therapies, including Roche’s giredestrant and Eli Lilly’s imlunestrant, solidify the trend toward personalized, biomarker-driven breast cancer care.
Supporting Data: The Case for De-escalation
The drive to reduce chemotherapy use is fueled by the results of the OPTIMA trial, which examined whether high-risk patients could avoid the toxicities of cytotoxic drugs. The study found that among those who opted for endocrine therapy alone, five-year invasive breast cancer-free survival was 93.7%, compared to 94.9% for those who underwent standard chemotherapy—a difference that researchers deemed statistically non-inferior.
While the data is promising, investigators acknowledge the constraints of the study. Robert Stein, the trial’s chief investigator, noted at the 2026 ASCO meeting that because the study recruited patients over nearly a decade, fewer than 40% have reached the five-year follow-up milestone. Consequently, statistical confidence intervals remain broad, necessitating further longitudinal study.
Despite these limitations, the evidence base for targeted, non-chemotherapeutic intervention is growing. In the I-SPY 2 sub-study, 20 women with stage II/III ER-positive, HER2-negative breast cancer received low-dose oral endoxifen prior to surgery. The trial showed a median reduction in Ki67—a critical marker of tumor cell proliferation—from 10.5% at baseline to 5% by the third week of treatment. Additionally, patients experienced observable tumor shrinkage on MRI scans, suggesting that endoxifen could serve as a powerful neoadjuvant (pre-surgical) treatment.
Official Responses and Strategic Implications
The leadership at Atossa Therapeutics views endoxifen as a versatile tool that could fit into multiple stages of the patient journey. Beyond its potential to shrink tumors before surgery—potentially allowing for less invasive surgical procedures and reduced reconstruction—the drug is also being positioned as an option for patient populations currently underserved by existing standards.
"A lot of times when men are diagnosed, they are sicker and further along in their trajectory," Rea notes. "If they do get treatment, they are limited in what they can take to prevent recurrence. Right now, that’s pretty much tamoxifen. We think endoxifen would also be good for that patient population, and for those who can’t take aromatase inhibitors because of pre-existing conditions like osteoporosis."
The broader oncology landscape is also responding. Companies such as Sermonix (via LeonaBio), Menarini (via Stemline), Roche, and Eli Lilly are all racing to develop next-gen SERMs and SERDs. These therapies target the same ER-positive, HER2-negative patient base, often focusing on those with ESR1 mutations who have progressed on earlier lines of endocrine therapy.
Implications for Future Oncology
The transition toward biomarker-driven treatment is the ultimate goal. The success of modern oncology is increasingly tied to understanding "tumor dynamics"—the specific metabolic and cellular attributes that drive growth.
"One of the things we’ve learned is that one size doesn’t fit all," Rea says. "It’s going to simply take data to get the FDA to accept a biomarker-driven treatment decision as grounds to skip chemo. We are seeing the FDA look more closely at biomarkers and evidence-based mechanisms of action. That’s something we’ll be able to leverage better than we could have a couple of years ago."
As the field moves toward a more nuanced understanding of cancer, the next three to five years are expected to yield a wave of new therapies that can "turn off" specific tumor growth signals. For patients, this could mean moving away from the "carpet bombing" approach of chemotherapy toward highly personalized, well-tolerated regimens that prioritize both long-term survival and quality of life.
While the path forward requires rigorous validation through larger, longer-term trials, the shift toward endoxifen and similar targeted agents represents a fundamental change in philosophy. By focusing on the biological drivers of the tumor rather than broad cytotoxic strategies, the medical community is inching closer to a future where breast cancer treatment is as precise as it is effective.
About the Author
